Clinical Trials in Plainfield, Indiana
17 recruiting
Showing 1–17 of 17 trials
Recruiting
Phase 3
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
Human Papilloma Virus (HPV)WartsCommon Warts+1 more
Verrica Pharmaceuticals Inc.600 enrolled4 locationsNCT07457918
Recruiting
Phase 2
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
Hidradenitis Suppurativa
Pfizer240 enrolled54 locationsNCT07228390
Recruiting
Phase 2
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
Atopic Dermatitis (AD)
Bluefin Biomedicine, Inc.225 enrolled55 locationsNCT07105488
Recruiting
Phase 1
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
Moderate-to-severe Atopic Dermatitis
Sitryx Therapeutics Ltd149 enrolled14 locationsNCT07558668
Recruiting
Phase 3
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
Actinic Keratosis
Sun Pharmaceutical Industries, Inc.160 enrolled10 locationsNCT07144345
Recruiting
Phase 3
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
Actinic Keratosis
Sun Pharmaceutical Industries, Inc.260 enrolled20 locationsNCT07144852
Recruiting
Phase 4
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
PsoriasisOverweight or Obesity
Eli Lilly and Company200 enrolled43 locationsNCT06857942
Recruiting
Phase 3
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
Atopic Dermatitis
Organon and Co180 enrolled48 locationsNCT07265479
Recruiting
Phase 3
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
Hidradenitis Suppurativa
Incyte Corporation550 enrolled107 locationsNCT06958211
Recruiting
Phase 2Phase 3
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS)
Bluefin Biomedicine, Inc.210 enrolled33 locationsNCT07287644
Recruiting
Phase 2
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
Plaque Psoriasis
Oruka Therapeutics, Inc.160 enrolled26 locationsNCT07290569
Recruiting
Phase 2
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
Chronic Spontaneous UrticariaChronic Inducible Urticaria
Blueprint Medicines Corporation105 enrolled47 locationsNCT06931405
Recruiting
Phase 2
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
Hidradenitis Suppurativa (HS)
Zura Bio Inc225 enrolled56 locationsNCT06993610
Recruiting
Phase 3
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
Human Papilloma Virus (HPV)WartsCommon Warts+1 more
Verrica Pharmaceuticals Inc.300 enrolled6 locationsNCT07246590
Recruiting
Phase 2
Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
Chronic Spontaneous Urticaria
Evommune, Inc.160 enrolled53 locationsNCT06873516
Recruiting
Phase 3
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
Androgenetic alopecia (AGA)Hair LossAGA+2 more
Veradermics, Inc.552 enrolled71 locationsNCT07146022
Recruiting
Phase 2
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
Atopic Dermatitis (AD)
CAGE Bio Inc.180 enrolled16 locationsNCT06810050